


How to read the Eyetelligence Report

Eyetelligence Assure Suite utilises deep learning to scan retinal images for features of eye and cardiovascular diseases. It presents these findings as low, medium, or high risk in the case of glaucoma, and as low or high risk for referable Diabetic Retinopathy and referable Age-related Macular Degeneration. In the case of CVD, the system provides 2 outputs which are absolute cardiovascular risk and cardiovascular health status.

The purpose is to provide you with information that you can consider and verify, in the context of other information, such as patient case history, and to determine if additional testing and / or referral or intervention may be warranted.

Report output page 1



Glaucoma

Glaucoma disc suspect defined as VCDR ≥ 0.7 or rim width ≤ 0.1 with or without RNFL defect or disc haemorrhage

High risk

Medium risk

Low risk

Diabetic Retinopathy

Classified as negative (no DR) and positive (moderate NPDR / mild DR / severe NPDR / proliferative DR) according to international council of ophthalmology guidelines.

Proliferative DR

Severe NPDR

Mild NPDR

Moderate NPDR

No DR

Severe and proliferating DR, if detected, should be referred to relevant specialist.

Age related Macular Degeneration

Classified as negative, early or intermediate, late dry and late wet AMD


Late wet

Late dry

Early or intermediate

Negative

Software session view:



Cardiovascular

Absolute cardiovascular risk indicates the risk (in percentage) of developing a heart attack or a stroke in 10-years' time based on retinal features, with $<10\%$ as low risk, $10-20\%$ as moderate risk and $\geq 20\%$ as high risk.

10%

Absolute Cardiovascular Risk

Cardiovascular health status score indicates the overall health status of the brain heart and blood vessel system. The score of 14% for instance indicates the patient is healthier than 13% of the population of his age and gender.

14%

Cardiovascular Health Status

Regulatory Disclaimer

Optain AI-enabled Eyetelligence Assure software is classified as a Class 1 medical device, with Australian TGA listing and European CE Mark, conforming to the performance and safety standards in over 30 countries across the EU and Australasia. For country-specific regulatory information, please contact your local Optain representative.

Eyetelligence Assure software is intended for the assessment of the retinal vascular system and to screen for microvascular health issues of the body, based on full colour fundus photos that are generated from a fundus camera. The Eyetelligence system outcomes are intended to be subsequently verified and certified by a qualified medical/eye care professional who will make a clinical decision based on a range of inputs not limited to Eyetelligence outcomes.